Short answer
Atrium Therapeutics, Inc. (RNA) filed an 8-K current report with the SEC on May 14, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Item 2.02 incorporates Exhibit 99.1, which contains Atrium Therapeutics’ fiscal-year 2026 results.
Atrium Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Item 2.02 incorporates Exhibit 99.1, which contains Atrium Therapeutics’ fiscal-year 2026 results
- Results are furnished, not filed, limiting direct Exchange Act Section 18 liability and incorporation by reference
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Atrium Therapeutics, Inc. 8-K filings
Get the next RNA 8-K as it lands
Follow RNA for push alerts, or ask the research agent what this filing means.